Schubert & Co’s Krystal Biotech KRYS Stock Holding History

Schubert & Co’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1	Closed	-$81	–	821
2023 Q1	$81	Hold	1	–	–	﹤0.01%	1613
2022 Q4	$79	Sell	1 -1	-50%	-$74	﹤0.01%	1594
2022 Q3	$0	Buy	+2	New	+$144	﹤0.01%	1475

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Schubert & Co's KRYS Position: Q2 2023 in Review

Schubert & Co sold out of Krystal Biotech (KRYS) in Q2 2023, closing a stake of 1 share — an estimated $81 sold.

Schubert & Co first reported a position in KRYS in Q3 2022 and held it in 3 quarters. The position peaked at $81 in Q1 2023. 183 funds tracked by Wall St. Rank hold KRYS as of Q2 2023.

Schubert & Co reported no remaining Krystal Biotech position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 1 Krystal Biotech share in Q2 2023, an estimated $81.
Schubert & Co first reported a position in Krystal Biotech in Q3 2022 and held it in 3 quarters.
Schubert & Co's Krystal Biotech position peaked at $81 in Q1 2023.
183 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.